Theratechnologies Seeks FDA Approval for EGRIFTA SV® Changes

Theratechnologies (TSE:TH) has released an update.

Theratechnologies has filed a Prior Approval Supplement with the FDA for changes in the manufacturing environment of EGRIFTA SV®, with existing inventory expected to meet demand until mid-January 2025. The company is in discussions with the FDA to expedite the release and prevent a potential product shortage. Theratechnologies will keep the market informed of any significant developments.

For further insights into TSE:TH stock, check out TipRanks’ Stock Analysis page.